Louisiana State Employees Retirement System reduced its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 6.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,900 shares of the medical research company’s stock after selling 500 shares during the period. Louisiana State Employees Retirement System’s holdings in Iqvia were worth $1,243,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in the business. C J Advisory Inc purchased a new stake in shares of Iqvia in the first quarter worth $27,000. Baystate Wealth Management LLC bought a new position in shares of Iqvia during the first quarter worth $27,000. Parkside Financial Bank & Trust boosted its position in shares of Iqvia by 140.2% during the first quarter. Parkside Financial Bank & Trust now owns 209 shares of the medical research company’s stock worth $30,000 after acquiring an additional 122 shares during the last quarter. GWM Advisors LLC boosted its position in shares of Iqvia by 306.7% during the first quarter. GWM Advisors LLC now owns 20,403 shares of the medical research company’s stock worth $46,000 after acquiring an additional 15,386 shares during the last quarter. Finally, Financial Gravity Wealth Inc. bought a new position in shares of Iqvia during the first quarter worth $68,000. 92.29% of the stock is owned by institutional investors and hedge funds.
Iqvia stock opened at $152.15 on Friday. The firm has a market capitalization of $30.77 billion, a PE ratio of 29.72, a price-to-earnings-growth ratio of 1.91 and a beta of 0.88. Iqvia Holdings Inc has a 12-month low of $104.90 and a 12-month high of $164.13. The firm has a 50-day moving average price of $157.85 and a 200-day moving average price of $144.02. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 1.72.
A number of brokerages recently weighed in on IQV. Svb Leerink began coverage on shares of Iqvia in a research report on Tuesday, May 28th. They set an “outperform” rating and a $160.00 target price for the company. JPMorgan Chase & Co. upped their target price on shares of Iqvia from $160.00 to $180.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. Mizuho upgraded shares of Iqvia from a “neutral” rating to a “buy” rating and upped their target price for the stock from $150.00 to $175.00 in a research report on Friday, June 21st. Zacks Investment Research upgraded shares of Iqvia from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Finally, TheStreet lowered shares of Iqvia from a “b” rating to a “c+” rating in a research report on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $161.13.
In related news, insider Kevin C. Knightly sold 6,945 shares of the firm’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $158.53, for a total value of $1,100,990.85. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Ari Bousbib sold 96,000 shares of the firm’s stock in a transaction dated Wednesday, June 19th. The stock was sold at an average price of $150.00, for a total transaction of $14,400,000.00. The disclosure for this sale can be found here. Insiders sold a total of 198,945 shares of company stock worth $30,860,991 in the last ninety days. 6.00% of the stock is currently owned by insiders.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also: Day Trading
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.